Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Second Generation Oral Norovirus Vaccine in Norovirus. The expected timing is based on the latest available company guidance and may change.
3/11/25- Ph1 initiated. 4/30/25- Enrollment completed. 6/11/25- Reported positive topline results. 9/10/25- Add'l Ph1 data reported. Subject to funding & partnering opportunities, initiate Ph2b before YE 2025 followed by EoPh2 w/ FDA. 10/20/25- Presentation at IDWeek'25. 11/13/25:- Additional supportive Ph1 data presented at multiple conferences. Next clinical trial expected to start in 2026. 03/12/26:- PR No update. 05/07/26:- Next generation bivalent norovirus candidate cross-reactivity data expected at meetings and publications later in 2026. 08/06/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.